glp-1 obesity drug news today oct 2025 Pipeline Update: August - Prime Therapeutics Eli Lilly to seek approval

NCT02205528 was a Phase 2 clinical trial of NNC0090-2746, and was designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled trial with open-label comparison, performed in patients with T2DM inadequately controlled with metformin (108 participants, 12 withdrew prematurely from the trial, 96 completed)

Explore our resultsDrag slider to compare See more patient journeys This treatment does not yet have a dedicated gallery

These players will face a steep challenge, especially as the market evolves, new bars for clinical outcomes are set, and unmet needs shift

Support weight loss Promote mental clarity Fight signs of aging Improve joint health Decrease muscle pain Improve skin tone & texture Reduce inflammation Bolster brain health Looking for the Perfect Gift

Digestive diseases (Basel, Switzerland)

Every half-life figure quoted for DSIP, on this page and everywhere else, comes from dogs, one monkey, and rats